COST

995.65

+1.42%↑

165.66

+0.9%↑

80.67

+0.2%↑

187.34

+1.24%↑

PEP

168.14

+0.53%↑

COST

995.65

+1.42%↑

165.66

+0.9%↑

80.67

+0.2%↑

187.34

+1.24%↑

PEP

168.14

+0.53%↑

COST

995.65

+1.42%↑

165.66

+0.9%↑

80.67

+0.2%↑

187.34

+1.24%↑

PEP

168.14

+0.53%↑

COST

995.65

+1.42%↑

165.66

+0.9%↑

80.67

+0.2%↑

187.34

+1.24%↑

PEP

168.14

+0.53%↑

COST

995.65

+1.42%↑

165.66

+0.9%↑

80.67

+0.2%↑

187.34

+1.24%↑

PEP

168.14

+0.53%↑

Home・Akcijų sąrašas・Lifecore Biomedical Inc

Lifecore Biomedical Inc

Atidarymo kaina

SektoriusVartotojų apsauga

7.2 1.12

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

7.13

Max

7.38

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-7.9M -10M
Pardavimai	-5.3M 31M
Pelno marža	-32.116
Darbuotojai	406

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-27

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-16M 225M
Ankstesnė atidarymo kaina	6.08
Ankstesnė uždarymo kaina	7.2

Naujienos nuotaikos

By Acuity

25%

75%

22 / 132 reitingas Consumer defensive

Lifecore Biomedical Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-23 22:53; UTC

Įsigijimai, susijungimai, perėmimai

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

2026-02-23 22:36; UTC

Uždarbis

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

2026-02-23 22:32; UTC

Uždarbis

Woodside Energy Fiscal Year Net Profit Falls 24%

2026-02-23 23:58; UTC

Rinkos pokalbiai

Uždarbis

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

2026-02-23 23:58; UTC

Rinkos pokalbiai

Uždarbis

Global Energy Roundup: Market Talk

2026-02-23 23:47; UTC

Rinkos pokalbiai

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

2026-02-23 23:43; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

2026-02-23 23:41; UTC

Įsigijimai, susijungimai, perėmimai

Crescent Capital Partners Owns 53% of ClearView Wealth

2026-02-23 23:40; UTC

Įsigijimai, susijungimai, perėmimai

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

2026-02-23 23:40; UTC

Įsigijimai, susijungimai, perėmimai

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

2026-02-23 23:40; UTC

Rinkos pokalbiai

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

2026-02-23 23:40; UTC

Įsigijimai, susijungimai, perėmimai

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

2026-02-23 23:39; UTC

Įsigijimai, susijungimai, perėmimai

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

2026-02-23 23:31; UTC

Uždarbis

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

2026-02-23 23:31; UTC

Uždarbis

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

2026-02-23 23:28; UTC

Uždarbis

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

2026-02-23 23:28; UTC

Uždarbis

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

2026-02-23 23:28; UTC

Uždarbis

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

2026-02-23 23:27; UTC

Uždarbis

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

2026-02-23 23:24; UTC

Rinkos pokalbiai

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

2026-02-23 22:38; UTC

Įsigijimai, susijungimai, perėmimai

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

2026-02-23 22:31; UTC

Uždarbis

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

2026-02-23 22:24; UTC

Uždarbis

Viva Energy Energy & Infrastructure Ebitda A$93 Million

2026-02-23 22:22; UTC

Uždarbis

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

2026-02-23 22:22; UTC

Uždarbis

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

2026-02-23 22:22; UTC

Uždarbis

Viva Energy FY Underlying Ebitda A$700.9 Million

2026-02-23 22:22; UTC

Uždarbis

Viva Energy Final Dividend 3.94 Australian Cents/Security

2026-02-23 22:21; UTC

Uždarbis

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

2026-02-23 22:21; UTC

Uždarbis

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

2026-02-23 22:20; UTC

Uždarbis

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Akcijų palyginimas

Kainos pokytis

Lifecore Biomedical Inc Prognozė

Bendras įvertinimas

By TipRanks

Pirkti

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių Lifecore Biomedical Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

22 / 132 reitingas Vartotojų apsauga

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Lifecore Biomedical Inc

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.